ASCO 2023 | Prognostic trials for 21-gene OncotypeDX in HR+/HER2- breast cancer with micrometastases

Nadeem Bilani, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the prospect of prognostic trials to confirm the value of the 21-gene OncotypeDX recurrence score to predict outcomes of premenopausal patients with HR+/HER2- breast cancer and lymph node micrometastasis. The current status is that there is no prospective clinical trial yet, but there is recognition of the need for one. Lymph node micrometastasis is not rare, constituting about 6% of patients. Previous trials have included only a small minority of patients with micrometastasis, making it crucial to develop prospective data to guide National Comprehensive Cancer Network (NCCN) guidelines for more specific recommendations. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.